Archives

Pareto Securities AS publishes buy recommendation for Epigenomics AG share

Berlin (Germany), December 23, 2022 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that Pareto Securities AS has published an updated research report upgrading Epigenomics AG’s share and issuing a buy recommendation. Pareto’s analyst highlights in particular the strong preclinical test results of Epi proColon “Next-Gen”, achieving a sensitivity of 84% with a specificity of 90%, well above the U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement threshold of 74%. Thereby, the Company’s “Multiomics” solution shows significantly improved performance characteristics compared to its predecessor test Epi proColon, which improves the early detection of colorectal cancer (CRC) and thus increases the performance of the new test. Should the performance data be confirmed in the FDA pivotal study, commercialization of the test is expected to start in in the second half of 2026.

Greg Hamilton, CEO of Epigenomics AG: “We are very pleased with the buy recommendation, which we believe reflects the strong test results Epi proColon “Next-Gen” has achieved in the preclinical study. The results are very meaningful as the 241 subjects include the impressive number of 70 CRC cases in total, which normally corresponds statistically to a sample size of around 17,000 subjects. For the upcoming clinical trial, the number of cancer cases in our pre-clinical data exceeds the necessary number to obtain FDA approval. We are very confident that our test will confirm the preclinical performance data in the prospective clinical trial and thus achieve reimbursement by CMS.”

The research update is available on the Company’s website in the News & Investors section.

About Epigenomics

Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics’ lead product is the blood test Epi proColon® for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. For the HCCBloodTest, a blood test for the detection of liver cancer, the company has received the CE mark for marketing in Europe.

For more information please visit www.epigenomics.com.

Contact:

Company
Epigenomics AG, Geneststraße 5, 10829 Berlin, Germany,
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com

Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise..

Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022

Berlin, Germany, December 21, 2022 – The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) again raises its earnings guidance for the current fiscal year 2022 due to lower costs, including, among others, lower study costs in 2022 for the prospective FDA pivotal study for Epi proColon “Next-Gen”.

For the full year 2022, the Executive Board now expects adjusted EBITDA (before share-based payment expenses) within the range of EUR -10.2 million to EUR -10.8 million and cash consumption within the range of EUR -13.5 million to EUR -14.0 million. Previously, the Company had expected EBITDA (before share-based payment expenses) and cash consumption to range from EUR -10.5 million to EUR -11.5 million and EUR -14.5 million to EUR -15.5 million, respectively. The revenue forecast remains unchanged within the range of EUR 0.3 million to EUR 0.8 million. The EBITDA forecast is subject to the development of the U.S. dollar in the remaining days of the year, which cannot yet be definitively predicted and may have an impact on the Company’s forecast.

Contact:
Company
Epigenomics AG, Geneststraße 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com

Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.